On September 14, GlaxoSmithKline PLC rose 3.32% in pre-market trading, trading at $49.73/share, with turnover of $848,600.

The stock gained momentum after the company announced that its lung cancer drug zidesamtinib (marketed as Jideytro) achieved a 94% overall response rate in previously untreated patients with advanced ROS1-positive non-small cell lung cancer. Notably, all trial participants with metastatic brain tumors responded to treatment, with 70% achieving complete tumor clearance. The safety profile was favorable, with treatment-related adverse events leading to dose reductions in only 11% of patients and discontinuations in just 1%.

Jideytro is GSK's first commercialized lung cancer drug, having previously received FDA approval for previously treated ROS1-positive lung cancer. The company plans to submit an application to the FDA this year to expand the drug's label to include first-line treatment. The strong efficacy data bolsters the drug's blockbuster sales potential and reinforces GSK's growing oncology pipeline, which has been a strategic priority alongside its cost-savings target of 1.9 billion pounds annually by 2029.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)